by Elana Gotkine HealthDay Reporter Progression-free survival is significantly longer with zanubrutinib than ibrutinib among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to a study published online Dec. 13 in the New England Journal of Medicine. Jennifer R. Brown, M.D., Ph.D., from the Dana-Farber Cancer Institute in Boston,...
